Home › Funds › REGENERON PHARMACEUTICALS, INC. › ACET

REGENERON PHARMACEUTICALS, INC. position in ACET

Adicet Bio, Inc. · Health Care

REGENERON PHARMACEUTICALS, INC. reported holding 60,511 shares of ACET (Adicet Bio, Inc.) in its Q3 2026 13F filing — a position valued at US$432K, representing 0.24% of its reported portfolio and ranking #3 among its reported holdings. REGENERON PHARMACEUTICALS, INC. has disclosed ACET holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)60.51K sh
Reported value held$432.05K
Portfolio Weight0.24%
First reportedQ4 2024
Last changeHold
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How REGENERON PHARMACEUTICALS, INC.'s ACET position evolved

REGENERON PHARMACEUTICALS, INC. first disclosed a stake in ACET in Q4 2024 at 968,183 shares (US$931K). Across 8 filings, REGENERON PHARMACEUTICALS, INC. increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 60,511 shares valued at US$432K. Notable position changes include a 94% trim in Q4 2025 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 968.18K $931.39K New
Q1 2025 968.18K $730.98K Hold
Q2 2025 968.18K $590.59K Hold
Q3 2025 968.18K $784.42K Hold
Q4 2025 60.51K $509.50K Reduce
Q1 2026 60.51K $412.08K Hold
Q2 2026 60.51K $522.82K Hold
Q3 2026 60.51K $432.05K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ACET and 13F data

ACET (Adicet Bio, Inc.) is a Health Care company. 27 other funds we track also report a position in ACET — the largest reported positions include Stonepine Capital Management, LLC (US$2.1M), Carlyle Group Inc. (US$1.6M), NEXTBio Capital Management LP (US$1.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ACET

All ACET fund holders →

FAQ

How long has REGENERON PHARMACEUTICALS, INC. held ACET?

REGENERON PHARMACEUTICALS, INC. has disclosed ACET holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is REGENERON PHARMACEUTICALS, INC.'s current position in ACET?

As of Q3 2026, REGENERON PHARMACEUTICALS, INC. holds 60.51K shares of ACET (Adicet Bio, Inc.), valued at $432.05K, representing 0.24% of its reported portfolio and ranking #3.

Has REGENERON PHARMACEUTICALS, INC. been buying or selling ACET?

In the latest 13F filing (Q3 2026), REGENERON PHARMACEUTICALS, INC. held unchanged its position in ACET.

Which other funds hold ACET?

Other major institutional holders of ACET include Stonepine Capital Management, LLC, Carlyle Group Inc., NEXTBio Capital Management LP, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.